Tempest Therapeutics, Inc. Repayment of Notes Receivable from Related Parties
Tempest Therapeutics, Inc. (TPST) reported Repayment of Notes Receivable from Related Parties of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RepaymentOfNotesReceivableFromRelatedParties · last filed 2023-03-22
- Tempest Therapeutics, Inc. repayment of notes receivable from related parties for the quarter ending 2021-12-31 was $0.00.
- Tempest Therapeutics, Inc. repayment of notes receivable from related parties for the quarter ending 2021-09-30 was $38.00K.
- Tempest Therapeutics, Inc. repayment of notes receivable from related parties for the quarter ending 2020-12-31 was $0.00.
- Tempest Therapeutics, Inc. repayment of notes receivable from related parties for the quarter ending 2020-09-30 was $0.00.
- Tempest Therapeutics, Inc. repayment of notes receivable from related parties for fiscal 2021 was $38.00K, a 13.64% decline from fiscal 2020.
- Tempest Therapeutics, Inc. repayment of notes receivable from related parties for fiscal 2020 was $44.00K.
| Period end | Repayment of Notes Receivable from Related Parties 1 month | Repayment of Notes Receivable from Related Parties 3 month | Repayment of Notes Receivable from Related Parties 6 month | Repayment of Notes Receivable from Related Parties 9 month | Repayment of Notes Receivable from Related Parties 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $38.00K derived: sum of 2 quarters · filed 2023-03-22 | $38.00K 10-K · filed 2023-03-22 | ||
| 2021-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $38.00K 10-Q · filed 2022-11-08 | |||
| 2021-08-31 | $38.00K 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $44.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $44.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $44.00K 10-Q · filed 2021-08-12 | ||||
| 2020-02-29 | $44.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |